Vol 7, No 4 (2006): Practical Diabetology
Review articles (submitted)
Published online: 2006-07-12
Get Citation

The role of the renin-angiotensin-aldosterone system blockade in preventing type 2 diabetes

Mariusz Dąbrowski, Elżbieta Kozek
Diabetologia Praktyczna 2006;7(4):265-279.
Vol 7, No 4 (2006): Practical Diabetology
Review articles (submitted)
Published online: 2006-07-12

Abstract

The prevalence of type 2 diabetes is still increasing. It causes both growing burden for health insurance institutions and growing social costs of disability and premature mortality related to diabetes. Searching for methods which can reduce incidence of diabetes and thus limit consequences of forthcoming epidemic becomes urgent. It is well known that lifestyle changes and some oral antidiabetic agents (metformin, acarbose, troglitazone, pioglitazone) can reduce risk of developing diabetes in persons with impaired glucose tolerance. Such effect has been proven also for statins (pravastatin), antiobesity agents (orlistat) and for antihypertensive drugs. In this paper, on the basis of several large scale randomized clinical trials, the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in prevention of type 2 diabetes is discussed. On the basis of experimental studies postulated mechanisms which can lead to reduction of the risk of developing diabetes are also presented. If thus observations will be confirmed by ongoing clinical studies directed to prevention of type 2 diabetes, the medical world will obtain a weapon which can diminish consequences and extent of expected epidemic of type 2 diabetes.

Abstract

The prevalence of type 2 diabetes is still increasing. It causes both growing burden for health insurance institutions and growing social costs of disability and premature mortality related to diabetes. Searching for methods which can reduce incidence of diabetes and thus limit consequences of forthcoming epidemic becomes urgent. It is well known that lifestyle changes and some oral antidiabetic agents (metformin, acarbose, troglitazone, pioglitazone) can reduce risk of developing diabetes in persons with impaired glucose tolerance. Such effect has been proven also for statins (pravastatin), antiobesity agents (orlistat) and for antihypertensive drugs. In this paper, on the basis of several large scale randomized clinical trials, the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in prevention of type 2 diabetes is discussed. On the basis of experimental studies postulated mechanisms which can lead to reduction of the risk of developing diabetes are also presented. If thus observations will be confirmed by ongoing clinical studies directed to prevention of type 2 diabetes, the medical world will obtain a weapon which can diminish consequences and extent of expected epidemic of type 2 diabetes.
Get Citation

Keywords

type 2 diabetes mellitus; prevention; angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; hypertension; insulin resistance

About this article
Title

The role of the renin-angiotensin-aldosterone system blockade in preventing type 2 diabetes

Journal

Clinical Diabetology

Issue

Vol 7, No 4 (2006): Practical Diabetology

Pages

265-279

Published online

2006-07-12

Bibliographic record

Diabetologia Praktyczna 2006;7(4):265-279.

Keywords

type 2 diabetes mellitus
prevention
angiotensin-converting enzyme inhibitor
angiotensin receptor blocker
hypertension
insulin resistance

Authors

Mariusz Dąbrowski
Elżbieta Kozek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl